Premium
Whither platelets after TAVR?
Author(s) -
Block Peter C.
Publication year - 2014
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.25739
Subject(s) - medicine , valve replacement , platelet , cardiology , adverse effect , major bleeding , stenosis , myocardial infarction
Key Points Thrombocytopenia after transcatheter aortic valve replacement (TAVR) is common and usually reaches 50–60% below baseline platelet levels. Adverse sequelae are rare but persistent thrombocytopenia is associated with increased mortality. Further studies identifying patients with comorbidities that lead to persistent thrombocytopenia and higher mortality might help identify patients with limited benefit from TAVR.